January
Tuesday 23 January 2018 photo 14/14
|
Mineralocorticoid receptor antagonist tolerability study guide: >> http://sga.cloudz.pw/download?file=mineralocorticoid+receptor+antagonist+tolerability+study+guide << (Download)
Mineralocorticoid receptor antagonist tolerability study guide: >> http://sga.cloudz.pw/read?file=mineralocorticoid+receptor+antagonist+tolerability+study+guide << (Read Online)
Download >> Download Mineralocorticoid receptor antagonist tolerability study guide. Read Online >> Read Online Mineralocorticoid receptor antagonist tolerability study guide 27 May 2013 Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart
27 May 2013 Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or . than the steroidal MRAs.6,7 The minerAlocorticoid Receptor Antagonist Tolerability Study (ARTS) was designed to assess the safety and tolerability of BAY
Purpose of review The broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs. Summary Novel, nonsteroidal MRAs are currently tested in clinical trials. Based on preclinical and first clinical data, these nonsteroidal MRAs might overcome the limitations of today's steroidal antagonists. aGlobal Drug
10 Feb 2015 Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
16 Sep 2015 Description: The goal of the trial was to evaluate treatment with the mineralocorticoid receptor antagonist finerenone compared with placebo among subjects with diabetes and albuminuria treated with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB). Contribution to
for the Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. IMPORTANCE Steroidal mineralocorticoid receptor antagonists, when added to a renin-angiotensin system blocker, further reduce proteinuria in patients with chronic kidney disease but may be underused
1 Feb 2015 Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): A randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Bertram Pitt, Stefan D. Anker, Michael Bohm,
Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
31 May 2016 Description: The goal of the trial was to evaluate treatment with the mineralocorticoid receptor antagonist finerenone compared with eplerenone among subjects with heart failure and type 2 diabetes mellitus, and/or chronic kidney disease. Unlike spironolactone and eplerenone, which are distributed to the
doi:10.1002/ejhf.218. Rationale and design of MinerAlocorticoid. Receptor antagonist Tolerability Study-Heart. Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Bertram Pitt1*, Stefan D. Anker2, Michael
Annons
Visa toppen
Show footer